Primary Outcome Measures:~Progression free survival~Secondary Outcome Measures:~Overall survival Safety analysis
This is a single arm Phase II study, in which 6 cycles of durvalumab with chemotherapy (Etoposide and Cisplatin) and durvalumab followed by Sequential radiotherapy for limited stage small cell lung cancer.